Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Swedish Orphan Biovitrum AB (publ)
Revenue
Swedish Orphan Biovitrum AB (publ)
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Revenue
kr26B
|
CAGR 3-Years
19%
|
CAGR 5-Years
13%
|
CAGR 10-Years
26%
|
|
|
Biogaia AB
STO:BIOG B
|
Revenue
kr1.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Revenue
kr997.9m
|
CAGR 3-Years
62%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Revenue
kr3.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
21%
|
|
|
Probi AB
STO:PROB
|
Revenue
kr630.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
18%
|
|
|
BioArctic AB
STO:BIOA B
|
Revenue
kr257.4m
|
CAGR 3-Years
123%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Swedish Orphan Biovitrum AB (publ)
Glance View
Swedish Orphan Biovitrum AB (publ), often known as Sobi, navigates the intricate world of biopharmaceuticals with a singular focus on developing and delivering innovative treatments for rare diseases. Founded in the heart of Scandinavia, Sobi has crafted a unique niche by addressing medical needs that are often overlooked by larger pharmaceutical companies. The company specializes in hematology and immunology, focusing on conditions where it can leverage its expertise to make a tangible difference. With a robust pipeline of biopharmaceutical products, Sobi dedicates itself to research and partnerships that not only drive scientific advancements but also ensure that its therapies reach the global market. This mission aligns with its deep commitment to patients whose conditions lack effective treatments. Sobi’s business model thrives on a blend of strategic acquisitions, rigorous clinical development, and expansive distribution capabilities. By acquiring promising therapies and collaborating with other innovators in the biotech space, it continually expands its product portfolio and market reach. Revenue flows primarily from the sales of these specialized therapies, which command premium pricing due to their targeted nature and the complex manufacturing processes involved. The company also invests significantly in its research and development programs, channeling insights from its interactions with healthcare professionals and patients to optimize its offerings. Through its relentless focus on rare diseases, Sobi not only secures financial returns but also significantly impacts the quality of life for patients, staying true to its foundational ethos.
See Also
What is Swedish Orphan Biovitrum AB (publ)'s Revenue?
Revenue
26B
SEK
Based on the financial report for Dec 31, 2024, Swedish Orphan Biovitrum AB (publ)'s Revenue amounts to 26B SEK.
What is Swedish Orphan Biovitrum AB (publ)'s Revenue growth rate?
Revenue CAGR 10Y
26%
Over the last year, the Revenue growth was 18%. The average annual Revenue growth rates for Swedish Orphan Biovitrum AB (publ) have been 19% over the past three years , 13% over the past five years , and 26% over the past ten years .
You don't have any saved screeners yet